Risk-based monitoring has been an accepted approach for over a decade, endorsed by both FDA guidance and ICH E6(R2), yet many teams still run it as "100% source data verification, minus a few visits" rather than as a genuinely different monitoring model. The difference matters, both for study quality and for monitoring cost.
RBM is a monitoring strategy, not a discount on monitoring
The most common implementation failure is treating RBM as a way to reduce site visit frequency without changing what happens during those visits, or how central monitoring fills the gap. Done properly, RBM redirects monitoring effort toward the risks that actually threaten data integrity and patient safety for your specific study, rather than distributing effort evenly across every data point regardless of risk.
Start with a genuine risk assessment, not a template
An RBM plan is only as good as the risk assessment underneath it. Generic risk categories copied from a previous study's plan will not reflect what actually threatens this study — a complex biomarker-driven endpoint, a first-time site network, a rare disease population with recruitment pressure. The risk assessment should be specific enough that someone reading it understands exactly why each critical data point and process was flagged.
Define your central monitoring triggers before the study starts
Central monitoring should not be a passive dashboard that someone glances at occasionally. It needs defined statistical and operational triggers — enrollment rate deviations, query aging beyond a threshold, protocol deviation clustering at a specific site — that automatically prompt a defined action. Without pre-agreed triggers, central monitoring data tends to accumulate without ever driving a decision.
Keep site-level monitoring plans genuinely differentiated
Not every site carries the same risk. A site with an experienced coordinator and a track record on your prior studies does not need the same visit intensity as a first-time site enrolling a complex population. RBM plans that apply identical monitoring intensity across all sites "for consistency" are not risk-based — they are standard monitoring with different paperwork.
Revisit the risk assessment, not just the visit schedule
Risk profiles change during a study — a site that starts strong can deteriorate, and a slow-enrolling site can stabilise. Many RBM plans are reviewed only for schedule adherence, not for whether the underlying risk assessment still reflects reality. Build a defined checkpoint, ideally quarterly, to reassess site and study-level risk and adjust the monitoring plan accordingly.
Document the rationale, not just the activity
An inspector reviewing an RBM approach will ask why visit frequency was reduced at a given site, not just confirm that it was. The rationale — the risk assessment, the trigger data, the decision to adjust — needs to be as well documented as the monitoring visits themselves. An RBM plan with no visible reasoning behind its decisions is difficult to defend, however sound those decisions actually were.
Where structured tools help
A consistently used tracker that captures monitoring visit findings and central monitoring triggers in one place makes RBM decisions easier to defend after the fact. Our Clinical Trial Monitoring Visit Tracker gives teams a practical structure for this. For teams building or reviewing a full RBM strategy, our Clinical Operations Excellence service includes risk-based monitoring plan design and review.